Netherlands aims to ensure stable drug supply after shortage

12 June 2017
netherlands_big

Dutch quango the Medicines Evaluation Board (MEB) has released its annual report, focusing on its role in ensuring the availability of medicines and reducing the use of animal testing in clinical development.

The MEB is an oversight body, established by law in the Netherlands, which assesses and monitors the safety and efficacy of medicines.

In its report for 2016, the group highlights the establishment of a dedicated medicine shortages and defects notification center as a key development in guaranteeing the availability of drugs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical